Published in Int J Oncol on August 07, 2013
EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII). Am J Cancer Res (2015) 1.29
The relationship between TTF-1 expression and EGFR mutations in lung adenocarcinomas. PLoS One (2014) 0.89
Molecular epidemiology of lung cancer and geographic variations with special reference to EGFR mutations. Transl Lung Cancer Res (2014) 0.86
Suitability of surgical tumor tissues, biopsy, or cytology samples for epidermal growth factor receptor mutation testing in non-small cell lung carcinoma based on chinese population. Transl Oncol (2014) 0.83
Analysis of the frequency of EGFR, KRAS and ALK mutations in patients with lung adenocarcinoma in Croatia. Diagn Pathol (2016) 0.77
Efficacy of bronchoscopic biopsy for the detection of epidermal growth factor receptor mutations and anaplastic lymphoma kinase gene rearrangement in lung adenocarcinoma. Thorac Cancer (2015) 0.77
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med (2004) 71.08
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (2004) 61.56
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med (2009) 46.35
Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med (2010) 27.12
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol (2012) 22.04
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol (2009) 21.94
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol (2011) 18.34
Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med (2009) 13.47
Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst (2005) 13.00
Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res (2004) 7.76
Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer. Clin Cancer Res (2006) 3.66
Relative abundance of EGFR mutations predicts benefit from gefitinib treatment for advanced non-small-cell lung cancer. J Clin Oncol (2011) 2.34
High resolution melting analysis for rapid and sensitive EGFR and KRAS mutation detection in formalin fixed paraffin embedded biopsies. BMC Cancer (2008) 2.16
Assessing EGFR mutations. N Engl J Med (2006) 1.83
Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma. Eur Respir J (2011) 1.74
EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples. J Clin Pathol (2012) 1.71
A comparison of ARMS and DNA sequencing for mutation analysis in clinical biopsy samples. J Exp Clin Cancer Res (2010) 1.68
Benchmarking of mutation diagnostics in clinical lung cancer specimens. PLoS One (2011) 1.65
An evaluation study of EGFR mutation tests utilized for non-small-cell lung cancer in the diagnostic setting. Ann Oncol (2012) 1.63
Competitive allele specific TaqMan PCR for KRAS, BRAF and EGFR mutation detection in clinical formalin fixed paraffin embedded samples. Exp Mol Pathol (2012) 1.48
High incidence of EGFR mutations in Korean men smokers with no intratumoral heterogeneity of lung adenocarcinomas: correlation with histologic subtypes, EGFR/TTF-1 expressions, and clinical features. J Thorac Oncol (2012) 1.44
EGFR mutation is specific for terminal respiratory unit type adenocarcinoma. Am J Surg Pathol (2005) 1.42
Epidermal growth factor receptor mutation detection using high-resolution melting analysis predicts outcomes in patients with advanced non small cell lung cancer treated with gefitinib. Clin Cancer Res (2007) 1.34
Prospective study of the accuracy of EGFR mutational analysis by high-resolution melting analysis in small samples obtained from patients with non-small cell lung cancer. Clin Cancer Res (2008) 1.31
Epidermal growth factor receptor mutations in lung cancers. Pathol Int (2007) 1.30
Pyrosequencing, a method approved to detect the two major EGFR mutations for anti EGFR therapy in NSCLC. J Exp Clin Cancer Res (2011) 1.25
Risk factors differ for non-small-cell lung cancers with and without EGFR mutation: assessment of smoking and sex by a case-control study in Japanese. Cancer Sci (2007) 1.24
Establishing an EGFR mutation screening service for non-small cell lung cancer - sample quality criteria and candidate histological predictors. Eur J Cancer (2011) 1.12
Association between age at diagnosis and the presence of EGFR mutations in female patients with resected non-small cell lung cancer. J Thorac Oncol (2010) 1.02
Optimized algorithm for Sanger sequencing-based EGFR mutation analyses in NSCLC biopsies. Virchows Arch (2012) 0.96
Impact of age on epidermal growth factor receptor mutation in lung cancer. Lung Cancer (2012) 0.92
Epidermal growth factor receptor mutation study for 5 years, in a population of patients with non-small cell lung cancer. Rev Port Pneumol (2012) 0.82
Rapid detection of epidermal growth factor receptor mutations with multiplex PCR and primer extension in lung cancer. J Biomed Sci (2010) 0.78
Monitoring of early response to neoadjuvant chemotherapy in stage II and III breast cancer by [18F]fluorodeoxyglucose positron emission tomography. J Clin Oncol (2006) 2.86
Prospective comparison of 3 gamma-probes for sentinel lymph node detection in 200 breast cancer patients. J Nucl Med (2005) 2.04
Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer. J Clin Oncol (2009) 1.99
FDG PET evaluation of early axillary lymph node response to neoadjuvant chemotherapy in stage II and III breast cancer patients. Eur J Nucl Med Mol Imaging (2011) 1.60
Real-time allele-specific amplification for sensitive detection of the BRAF mutation V600E. Mol Cell Probes (2004) 1.39
Mucosal IL-10 and TGF-beta play crucial roles in preventing LPS-driven, IFN-gamma-mediated epithelial damage in human colon explants. J Clin Invest (2008) 1.38
Prospective preoperative mediastinal lymph node staging by integrated positron emission tomography-computerised tomography in patients with non-small-cell lung cancer. Eur J Cardiothorac Surg (2009) 1.30
Sentinel lymph node biopsy after neoadjuvant chemotherapy for advanced breast cancer: results of Ganglion Sentinelle et Chimiotherapie Neoadjuvante, a French prospective multicentric study. J Clin Oncol (2008) 1.26
Inhibition of RhoA/Rho kinase pathway is involved in the beneficial effect of sildenafil on pulmonary hypertension. Br J Pharmacol (2005) 1.24
Up-regulated expression of ADAM17 in human colon carcinoma: co-expression with EGFR in neoplastic and endothelial cells. J Pathol (2005) 1.20
Zoledronic acid potentiates mTOR inhibition and abolishes the resistance of osteosarcoma cells to RAD001 (Everolimus): pivotal role of the prenylation process. Cancer Res (2010) 1.10
Pathologic complete response to trastuzumab-based neoadjuvant therapy is related to the level of HER-2 amplification. Clin Cancer Res (2007) 1.04
Active smoking compromises IVF outcome and affects ovarian reserve. Reprod Biomed Online (2008) 1.04
Developing cell therapy techniques for respiratory disease: intratracheal delivery of genetically engineered stem cells in a murine model of airway injury. Hum Gene Ther (2009) 1.01
Identification of secreted CD155 isoforms. Biochem Biophys Res Commun (2003) 0.98
Enteric glia modulate epithelial cell proliferation and differentiation through 15-deoxy-12,14-prostaglandin J2. J Physiol (2010) 0.97
Comparison of immunohistochemistry, DNA sequencing and allele-specific PCR for the detection of IDH1 mutations in gliomas. Int J Oncol (2012) 0.95
Identification of novel markers for the diagnosis of malignant pleural mesothelioma. Am J Pathol (2011) 0.95
[Update of the GEFPICS' recommendations for HER2 status determination in breast cancers in France]. Ann Pathol (2010) 0.94
Position in cell cycle controls the sensitivity of colon cancer cells to nitric oxide-dependent programmed cell death. Cancer Res (2004) 0.93
Plasma is a better source of tumor-derived circulating cell-free DNA than serum for the detection of EGFR alterations in lung tumor patients. Lung Cancer (2013) 0.93
Involvement of the serrated neoplasia pathway in inflammatory bowel disease-related colorectal oncogenesis. Oncol Rep (2007) 0.91
Aberrant splicing and protease involvement in mesothelin release from epithelioid mesothelioma cells. Cancer Sci (2007) 0.90
Expression of NOS1 and soluble guanylyl cyclase by human kidney epithelial cells: morphological evidence for an autocrine/paracrine action of nitric oxide. Kidney Int (2003) 0.90
Ovarian reserve in young women of reproductive age with Crohn's disease. Inflamm Bowel Dis (2011) 0.90
Human colonic myocytes are involved in postischemic inflammation through ADAM17-dependent TNFalpha production. Br J Pharmacol (2006) 0.89
KLF4-dependent, PPARgamma-induced expression of GPA33 in colon cancer cell lines. Int J Cancer (2009) 0.89
Monitoring multiple myeloma patients treated with daratumumab: teasing out monoclonal antibody interference. Clin Chem Lab Med (2016) 0.87
Clinical and survival impact of FDG PET in patients with suspicion of recurrent cervical carcinoma. Eur J Nucl Med Mol Imaging (2010) 0.85
TACE inhibition amplifies TNF-alpha-mediated colonic epithelial barrier disruption. Int J Mol Med (2009) 0.85
ADAM15 upregulation and interaction with multiple binding partners in inflammatory bowel disease. Lab Invest (2006) 0.85
Pure flat epithelial atypia (DIN 1a) on core needle biopsy: study of 60 biopsies with follow-up surgical excision. Breast Cancer Res Treat (2010) 0.85
β1, β2, and β3 adrenoceptors and Na+/H+ exchanger regulatory factor 1 expression in human bronchi and their modifications in cystic fibrosis. Am J Respir Cell Mol Biol (2010) 0.84
Validation of axillary sentinel lymph node detection in the staging of early lobular invasive breast carcinoma: a prospective study. Cancer (2004) 0.84
Effect of Extrinsic and Intrinsic Stressors on Clinical Skills Performance in Third-Year Medical Students. J Gen Intern Med (2015) 0.83
New chondrosarcoma cell lines and mouse models to study the link between chondrogenesis and chemoresistance. Lab Invest (2013) 0.82
Loss of expression of TIMP3 in clear cell renal cell carcinoma. Eur J Cancer (2010) 0.82
Ovarian reserve and in vitro fertilization cycles outcome according to women smoking status and stimulation regimen. Arch Gynecol Obstet (2011) 0.81
CCL2, galectin-3, and SMRP combination improves the diagnosis of mesothelioma in pleural effusions. J Thorac Oncol (2012) 0.81
Vasoactive intestinal peptide induces IL-8 production in human colonic epithelial cells via MAP kinase-dependent and PKA-independent pathways. Biochem Biophys Res Commun (2004) 0.81
Detection of EGFR mutations in the plasma of patients with lung adenocarcinoma for real-time monitoring of therapeutic response to tyrosine kinase inhibitors? J Thorac Oncol (2014) 0.80
Reduction of free immunoglobulin light chains using adsorption properties of hemodiafiltration with endogenous reinfusion. Blood Purif (2010) 0.80
Paraffin-embedded tissue is less accurate than frozen section analysis for determining VHL mutational status in sporadic renal cell carcinoma. Urol Oncol (2010) 0.80
Stress responses in medical students in ambulatory and in-hospital patient consultations. Med Educ (2011) 0.78
Plasma PCSK9 is a late biomarker of severity in patients with severe trauma injury. J Clin Endocrinol Metab (2013) 0.78
HtrA3 is regulated by 15-deoxy-Delta12,14-prostaglandin J2 independently of PPARgamma in clear cell renal cell carcinomas. Biochem Biophys Res Commun (2009) 0.77
Rabbit antithymocyte globulin-induced serum sickness disease and human kidney graft survival. J Clin Invest (2015) 0.76
The PPAR(gamma) K422Q mutation does not contribute to troglitazone inefficiency in colon cancer treatment. Cancer Lett (2005) 0.76
Response to: Interference of daratumumab on the serum protein electrophoresis. Clin Chem Lab Med (2016) 0.75
Low expression of ORF4, a dominant negative variant of peroxisome proliferator-activated receptor gamma, in colorectal adenocarcinoma. Oncol Rep (2007) 0.75
Disseminated Mucormycosis With Cerebral Involvement Owing to Rhizopus Microsporus in a Kidney Recipient Treated With Combined Liposomal Amphotericin B and Posaconazole Therapy. Exp Clin Transplant (2014) 0.75
Readers and authors respond to "introducing the doctor of nursing practice". MedGenMed (2006) 0.75
Long-term outcome of monoclonal (type 1) cryoglobulinemia. Am J Hematol (2014) 0.75
[Cholangiocarcinomas developing on multiple bile duct hamartomas syndrome]. Ann Pathol (2009) 0.75
Severe pulmonary hypertension leading to heart-lung transplantation and revealing breast cancer. Eur Respir J (2012) 0.75
PPARγ is functionally expressed in clear cell renal cell carcinoma. Int J Oncol (2010) 0.75
Margin width should not still enforce a systematic surgical re-excision in the conservative treatment of early breast infiltrative ductal carcinoma. Ann Surg Oncol (2013) 0.75
[Pathological form in breast cancer: setting and evaluation of a professional pratice]. Ann Pathol (2009) 0.75
[The solitary rectal ulcer syndrome]. Gastroenterol Clin Biol (2006) 0.75
Identification of 5-fluorocytosine as a new interfering compound in serum capillary zone electrophoresis. Clin Chem Lab Med (2016) 0.75
Growth inhibitory effect of celecoxib and rofecoxib on human colorectal carcinoma cell lines. Anticancer Res (2005) 0.75